Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy?

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $15.90, but opened at $18.00. Structure Therapeutics shares last traded at $17.69, with a volume of 145,502 shares changing hands.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Stifel Nicolaus began coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target for the company. William Blair initiated coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $81.29.

Structure Therapeutics Stock Performance

The business has a fifty day moving average of $20.23 and a 200-day moving average of $28.51. The company has a market capitalization of $1.25 billion, a P/E ratio of -29.41 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. ANTIPODES PARTNERS Ltd grew its holdings in Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after buying an additional 553 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Structure Therapeutics during the fourth quarter worth about $34,000. FNY Investment Advisers LLC purchased a new position in Structure Therapeutics during the fourth quarter worth about $40,000. Finally, Virtus ETF Advisers LLC lifted its position in shares of Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after buying an additional 455 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.